NewsBenzingaレボリューション・メディシンズのRASONQUE+化学療法、転移性膵臓がん一次治療患者61例で18.3か月の中央値追跡時に確認済みORR 60.7%、完全奏効8.2%を示す;第3相RASolute 303を支持 レボリューション・メディシンズのRASONQUE+化学療法、転移性膵臓がん一次治療患者61例で18.3か月の中央値追跡時に確認済みORR 60.7%、完全奏効8.2%を示す;第3相RASolute 303を支持 Benzinga 2026.11.20 05:38 (GMT+0) Open on Benzinga Other news Geospace Technologies (GEOS) Shares Tumble 16.47% After Hours: Here's Why Stock Market: Will S&P 500 Open Up or Down Today? Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY Morning Bid: Anthropic's splashy IPO fails to lift AI boat Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303 Onfolio Holdings (ONFO) Stock Drops 16.80% After Hours: Here's What Investors Should Know
Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303